Cargando…
Calcifediol: Why, When, How Much?
Vitamin D deficiency is a constantly growing health problem worldwide. Adults affected with hypovitaminosis D could experience negative consequences on their musculoskeletal system and extra-skeletal health. In fact, an optimal vitamin D status is essential to ensure the correct bone, calcium, and p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222038/ https://www.ncbi.nlm.nih.gov/pubmed/37242420 http://dx.doi.org/10.3390/ph16050637 |
_version_ | 1785049600525074432 |
---|---|
author | Donati, Simone Marini, Francesca Giusti, Francesca Palmini, Gaia Aurilia, Cinzia Falsetti, Irene Iantomasi, Teresa Brandi, Maria Luisa |
author_facet | Donati, Simone Marini, Francesca Giusti, Francesca Palmini, Gaia Aurilia, Cinzia Falsetti, Irene Iantomasi, Teresa Brandi, Maria Luisa |
author_sort | Donati, Simone |
collection | PubMed |
description | Vitamin D deficiency is a constantly growing health problem worldwide. Adults affected with hypovitaminosis D could experience negative consequences on their musculoskeletal system and extra-skeletal health. In fact, an optimal vitamin D status is essential to ensure the correct bone, calcium, and phosphate homeostasis. To improve vitamin D status, it is important to not only increase the intake of food fortified with vitamin D, but also to administer vitamin D supplementation when required. Vitamin D3 (cholecalciferol) is the most widely used supplement. In recent years, the administration of calcifediol (25(OH)D3), the direct precursor of the biologically active form of vitamin D3, as oral vitamin D supplementation has progressively grown. Here, we report the potential medical benefits of some peculiar biological actions of calcifediol, discussing the possible specific clinical scenarios in which the oral intake of calcifediol could be most effective to restore the correct serum levels of 25(OH)D3. In summary, the aim of this review is to provide insights into calcifediol-related rapid non-genomic responses and the possible use of this vitamin D metabolite as a supplement for the treatment of people with a higher risk of hypovitaminosis D. |
format | Online Article Text |
id | pubmed-10222038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102220382023-05-28 Calcifediol: Why, When, How Much? Donati, Simone Marini, Francesca Giusti, Francesca Palmini, Gaia Aurilia, Cinzia Falsetti, Irene Iantomasi, Teresa Brandi, Maria Luisa Pharmaceuticals (Basel) Review Vitamin D deficiency is a constantly growing health problem worldwide. Adults affected with hypovitaminosis D could experience negative consequences on their musculoskeletal system and extra-skeletal health. In fact, an optimal vitamin D status is essential to ensure the correct bone, calcium, and phosphate homeostasis. To improve vitamin D status, it is important to not only increase the intake of food fortified with vitamin D, but also to administer vitamin D supplementation when required. Vitamin D3 (cholecalciferol) is the most widely used supplement. In recent years, the administration of calcifediol (25(OH)D3), the direct precursor of the biologically active form of vitamin D3, as oral vitamin D supplementation has progressively grown. Here, we report the potential medical benefits of some peculiar biological actions of calcifediol, discussing the possible specific clinical scenarios in which the oral intake of calcifediol could be most effective to restore the correct serum levels of 25(OH)D3. In summary, the aim of this review is to provide insights into calcifediol-related rapid non-genomic responses and the possible use of this vitamin D metabolite as a supplement for the treatment of people with a higher risk of hypovitaminosis D. MDPI 2023-04-22 /pmc/articles/PMC10222038/ /pubmed/37242420 http://dx.doi.org/10.3390/ph16050637 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Donati, Simone Marini, Francesca Giusti, Francesca Palmini, Gaia Aurilia, Cinzia Falsetti, Irene Iantomasi, Teresa Brandi, Maria Luisa Calcifediol: Why, When, How Much? |
title | Calcifediol: Why, When, How Much? |
title_full | Calcifediol: Why, When, How Much? |
title_fullStr | Calcifediol: Why, When, How Much? |
title_full_unstemmed | Calcifediol: Why, When, How Much? |
title_short | Calcifediol: Why, When, How Much? |
title_sort | calcifediol: why, when, how much? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222038/ https://www.ncbi.nlm.nih.gov/pubmed/37242420 http://dx.doi.org/10.3390/ph16050637 |
work_keys_str_mv | AT donatisimone calcifediolwhywhenhowmuch AT marinifrancesca calcifediolwhywhenhowmuch AT giustifrancesca calcifediolwhywhenhowmuch AT palminigaia calcifediolwhywhenhowmuch AT auriliacinzia calcifediolwhywhenhowmuch AT falsettiirene calcifediolwhywhenhowmuch AT iantomasiteresa calcifediolwhywhenhowmuch AT brandimarialuisa calcifediolwhywhenhowmuch |